Merck & Co., Inc. CEDEAR Logo

Merck & Co., Inc. CEDEAR (MRK)

BCBA

Currency in ARS
48,560.00
+1,340.00 (+2.84%)

Closed

Aug 21, 2026

Day's Range

47,380.00
49,000.00

52 wk Range

21,600.00
49,000.00

Profile - MRK - Merck & Co., Inc. CEDEAR

Profile

Mic Code

XBUE

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

73K


Merck & Co., Inc. CEDEAR is an Argentine depositary receipt that represents an economic interest in shares of Merck & Co., Inc., a global biopharmaceutical company focused on prescription medicines, vaccines, and animal health products. Its primary purpose is to provide local investors peso-denominated access to Merck’s international equity exposure through the domestic market, with pricing that reflects the underlying U.S. share adjusted by the CEDEAR conversion ratio and prevailing currency dynamics. The program references the U.S.-listed company known for oncology, vaccines, infectious diseases, and cardiometabolic therapies, enabling participation in one of the world’s major pharmaceutical franchises from Argentina. Notably, this CEDEAR is structured with a defined ratio between receipts and the underlying security, a feature that facilitates portfolio sizing, corporate action pass-throughs, and comparability to the reference stock. Within the local market, it functions as a vehicle for diversification and sector exposure to global healthcare, while aligning settlement, custody, and disclosure practices with Argentina’s market infrastructure and CEDEAR program standards.

Profile Details

Type

Depositary Receipt

Ceo

Mr. Robert M. Davis J.D.

Address

126 East Lincoln Avenue

City

Rahway

State

NJ

Zip

07065

Country

United States

Phone

908 740 4000

Key Executives - MRK - Merck & Co., Inc. CEDEAR

Key executives

NamePositionAgePay
Mr. Robert M. Davis J.D.Chairman, President & CEO586.88B
Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller58-
Mr. David Michael WilliamsExecutive VP and Chief Information & Digital Officer56-
Mr. Peter DannenbaumVice President of Investor Relations--
Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories624.46B
Ms. Caroline A. LitchfieldExecutive VP & CFO563.57B
Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer493.41B
Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel473.23B
Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health623.22B
Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications592.29B

Cross Listings - MRK - Merck & Co., Inc. CEDEAR

Also listed on

The same company trading on other exchanges.

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Charting by TradingView.

Last updated:

Stocks news

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.